PRIDE Surveillance Projects Data Packaging Project Information Package Specification Version 1.1

Kelleher, Daniel; Shipp, Robert L.; Mason, James David

doi:10.2172/1009119

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparisons between categorical characteristics and hormone concentrations were performed by using censored regression models 27 assuming a log‐normal distribution for GDF9 and BMP15 concentrations, which were confirmed to be appropriate based on Q−Q plots 28 . Associations between hormone concentrations and continuous characteristics, as well as between pairs of hormone concentrations, were estimated using the NADA R package, 29 which produces a version of Kendall's tau correlation coefficient that allows for doubly censored data, 30 as well as its estimated asymptotic standard error. This was used to produce 95% confidence intervals (CI) for the correlation estimates and perform global Wald tests for interaction analysis of differences in correlations between groups ( p (int)).…”

Section: Methodsmentioning

confidence: 99%

Serum GDF9 and BMP15 as potential markers of ovarian function in women with and without polycystic ovary syndrome

Riepsamen

Donoghoe²,

Indran

et al. 2022

Clinical Endocrinology

View full text Add to dashboard Cite

Objective Growth differentiation factor‐9 (GDF9) and bone morphogenetic protein‐15 (BMP15) are critical paracrine regulators of female fertility and are predominantly expressed by oocytes. However, it is unknown if serum concentrations reflect changes in ovarian function and/or reproductive endocrine disorders. This study aimed to determine if serum GDF9/BMP15 are associated with ovarian, pituitary, oestrogenic, androgenic and metabolic characteristics and the ovarian pathologies, polycystic ovarian morphology (PCOM) and polycystic ovary syndrome (PCOS). Design Women aged 21−45 years (n = 381) were included from a cross‐sectional study at the National University Hospital, Singapore. Patients: Participants were volunteers and patients with possible PCOS. Measurements: Anthropometric measurements, transvaginal ultrasound scans and serum sampling were performed and a questionnairecompleted. Serum GDF9 and BMP15 concentrations were matched with menstrual cycle length, ovarian protein and steroid hormone production, pituitary hormone production and metabolic assessments in women with PCOM or PCOS and those with neither (control). Results Serum GDF9 and BMP15 were detectable in 40% and 41% of women, respectively and were positively correlated with each other (r = 0.08, p = 0.003). GDF9, but not BMP15, was positively correlated with ovarian volume (p = 0.02) and antral follicle count (AFC) (p = 0.004), but not with anti‐Müllerian hormone (p = 0.05). However, serum GDF9 and BMP15 concentrations were not significantly different between control, PCOM and PCOS women, nor associated with androgenic or metabolic PCOS features. However, the relationship between GDF9 and AFC differed between control, PCOM and PCOS women (p = 0.02). Conclusions Serum GDF9 and BMP15 concentrations somewhat reflect ovarian but not androgenic or metabolic characteristics of PCOS, with increased GDF9 reflecting high AFC as seen in PCOM/PCOS.

show abstract

Section: Methodsmentioning

confidence: 99%

Serum GDF9 and BMP15 as potential markers of ovarian function in women with and without polycystic ovary syndrome

Riepsamen

Donoghoe²,

Indran

et al. 2022

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Because many of these concentrations were below the limit of quantitation (LOQ; 0–98% of the samples for each analyte), we calculated the sum of the PFAS analytes using the Kaplan–Meier techniques (Helsel 2012). The Kaplan–Meier sums for each sample were calculated in R Ver 3.4.3 (R Core Team 2017) with the function cenfit in the package NADA Ver 1.6‐1.1 (Lee 2017) by multiplying the Kaplan–Meier mean by the number of analytes (Helsel 2012).…”

Section: Methodsmentioning

confidence: 99%

Trends and Patterns of Perfluoroalkyl Substances in Blood Plasma Samples of Bald Eagle Nestlings in Wisconsin and Minnesota, USA

Dykstra¹,

Route

Williams

2020

Enviro Toxic and Chemistry

View full text Add to dashboard Cite

We analyzed concentrations and trends of perfluoroalkyl substances (PFAS) in blood plasma samples of bald eagle (Haliaeetus leucocephalus) nestlings at 6 study areas in the upper Midwest of the United States, 2006 to 2015, and long-term trends at 2 Lake Superior (USA/Canada) sites, 1995 to 2015. Nestling blood plasma concentrations of the sum of 15 PFAS analytes (∑PFAS) differed among study areas and were highest at the 3 industrialized river sites: pools 3 and 4 of the Mississippi River (pools 3 + 4; geometric mean [GM] = 754 μg/L; range = 633-2930), the Mississippi National River and Recreational Area (GM = 687 μg/L; range = 24-7371), and the lower St. Croix National Scenic Riverway (GM = 546 μg/L; range = 20-2400). Temporal trends in ∑PFAS in nestling plasma differed among study areas; concentrations decreased at pools 3 + 4, Mississippi National River and Recreational Area, and lower St. Croix National Scenic Riverway, but not at the most remote sites, the upper St. Croix River and Lake Superior. Overall, perfluorooctanesulfonate (PFOS) was the most abundant analyte at all study areas, and perfluorodecanesulfonate (PFDS) the second most abundant at industrialized river sites although not at Lake Superior; concentrations of both these analytes declined from 2006 to 2015 over the study area. In addition, nestling age significantly influenced plasma concentrations of ∑PFAS and 7 of the 12 analytes. For these analytes, concentrations increased by 1 to 2%/d as nestlings grew, indicating that age should be considered when using nestling plasma to assess PFAS.

show abstract

PRIDE Surveillance Projects Data Packaging Project Information Package Specification Version 1.1

Cited by 2 publications

References 0 publications

Serum GDF9 and BMP15 as potential markers of ovarian function in women with and without polycystic ovary syndrome

Serum GDF9 and BMP15 as potential markers of ovarian function in women with and without polycystic ovary syndrome

Trends and Patterns of Perfluoroalkyl Substances in Blood Plasma Samples of Bald Eagle Nestlings in Wisconsin and Minnesota, USA

Contact Info

Product

Resources

About